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Chemotherapy. METHODS: An analysis of the IMS Health
ONCO Combined, LMPH, EHPP, GERS databases allowed
identifying the anti-emetic schemes used in this indication in
2002, to draw up the market trend in ambulatory care and in
hospital, and to determine the cost of corresponding consump-
tion. A budget impact model was built over 4 years with several
scenarii. The results are reported for 10,000 HEC cycles with a
reduction in the use of the cisplatin of 5% per year, a 10%, 15%,
20%, 25% penetration rate of aprepitant, and a substitution rate
in the delayed phase increasing from 30% to 90% over the
period. RESULTS: The market share of 5-HT3 receptor antago-
nists was equal to 76% of the HEC market in 2002. In ambu-
latory care, the average cost of setrons in acute phase d1 and
both in acute and delayed phases amounts respectively €26.90
and €111.25 per chemotherapy cycle. In hospital the corre-
sponding ﬁgures are €33.02 and €147.50. The antiemetic treat-
ment cost without aprepitant rises to €774,000 the ﬁrst year 
and to €664,000 the fourth year. The net budget impact due to
the introduction of aprepitant is €46,000 the ﬁrst year and
€41,000 the fourth year, i.e. less than 6% each year. In ambula-
tory care, this differential is €23,000 the ﬁrst year and becomes
nearly null cost over the four years. CONCLUSION: The 
overcost generated by the use of aprepitant is small for the
French sickness funds compared to the overall antiemetic 
treatment cost.
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OBJECTIVES: The aim of this study was to estimate costs of
care associated with metastatic colorectal cancer (MCCR) in
current clinical practice and the potential impact on the Spanish
health care budget of cetuximab prescription to patients with
MCCR. METHODS: In order to describe treatment patterns and
to analyse costs of MCCR, a cost of care treatment model was
constructed. The economic impact of cetuximab was estimated
by means of a treatment model for third-line use of the cetux-
imab combination after second-line irinotecan failure. Treatment
patterns were obtained from questionnaires ﬁlled out by 14
Spanish hospitals and from an advisory board of 5 clinical
experts. Treatment algorithms were constructed by using Tree
Age Data Pro software. In order to estimate the unit costs, Diag-
nostic Related Groups were used for inpatient services, while
outpatient services were calculated on daily based rates. Unit
costs were obtained from national databases (€2004). The treat-
ment costs were calculated from the perspective of the Spanish
National Health System. The incidence of MCCR was obtained
from literature review. RESULTS: For a population of 10,350
patients with MCCR in Spain, the total cost (pharmacological
and medical costs) was estimated in €151 million. In that sce-
nario, the cost of care of patients at third-line therapy that had
failed to irinotecan therapy amounted €1.5 million. With the
introduction of cetuximab after second-line irinotecan failure, a
maximum of 193 patients were estimated to be eligible for the
new drug. In this scenario, the total cost of the third-line therapy
would come to €4.7 million. CONCLUSIONS: Cetuximab in
combination with irinotecan is the only third-line therapy indi-
cated in MCCR after irinotecan failure. If the eligible patients in
third-line therapy received cetuximab and irinotecan instead of
current clinical practice, the economic impact of substitution
would amount €3.2 million.
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OBJECTIVES: To evaluate direct treatment cost associated with
pegylated liposomal doxorubicin hydrochloride (PLD) and
topotecan used as second line therapies for ovarian cancer in
Poland. METHODS: The literature review showed topotecan
and PLD have similar efﬁcacy in platinum-refractory or platinum
resistant advanced ovarian cancer but different adverse events
proﬁle. The cost-minimization analysis was performed from the
payer’s perspective. Only direct medical costs (i.e. drug acquisi-
tion costs, drug administration costs and managing adverse
events costs) were included. Based on epidemiological data bud-
getary impact of PLD treatment in Poland was estimated.
RESULTS: The acquisition and drug administration costs were
estimated at €12,448 and €6935 for PLD and topotecan, while
cost of managing adverse events at €134 and €1234 for PLD and
topotekan, respectively. The total cost per patient summed up to
€12,882 for PLD and €8169 for topotecan. 38% reduction in
acquisition cost of PLD would balance topotecan associated
costs. Epidemiological data indicated 985 platinum-resistant or
platinum-refractory ovarian cancer patients in Poland were eli-
gible annually for treatment with PLD, thus additional cost could
be estimated at €4.64 million. CONCLUSIONS: PLD represents
attractive treatment strategy in second line therapy of platinum-
resistant or platinum-refractory ovarian cancer, although acqui-
sition cost reduction is necessary were compared to topotecan in
Polish settings.
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The clinical study phase III 071 has showed the new antiemetic
Aprepitant in association with a standard therapy (corticosteroid
plus a 5-HT3 receptor antagonist) increases signiﬁcantly the
complete response (no vomiting and no rescue treatment) by
more than 10 points compared to the standard therapy used in
MEC. OBJECTIVES: To evaluate the budget impact implied by
the introduction of this new antiemetic on the French sickness
funds. METHODS: The MEC were deﬁned according to the rec-
ommendations of the Multinational Association of Supportive
Care in Cancer (2004). A sample of patients was extracted from
the ONCO IMS 2004 database. The inclusion criteria used were:
to receive a MEC in association with an antiemetic one con-
taining a corticosteroid and a 5-HT3 receptor antagonist and to
have this treatment during the acute and delayed periods. Prices
of the antiemetic treatments were taken from the GERS 2004
database. A budget impact model was implemented over a period
of four years, based on a stable population and on different pen-
etration and substitution rates of Aprepitant. RESULTS: The
results are reported for 10,000 MEC cycles associated to the
standard therapy. The penetration and substitution rates of
Aprepitant increase over the period from 10% to 25% and from
70% to 95%, respectively. In 2004, the treatment cost is
€466,000. The introduction of Aprepitant increases the cost of
the acute phase but decreases it in the delayed one. In the ambu-
